Latanoprost eye drops class of drug:
Glaucoma. Prostanoid-selective prostaglandin F (FP) receptor agonist.
Latanoprost eye drops indications:
Reduction of elevated IOP in patients with OAG or ocular hypertension.
Latanoprost eye drops dosage form:
Topical ophthalmic solution 0.005% (50 μg/ml).
Latanoprost eye drops dose:
1 drop to affected eye(s) once per day in the evening; dosage should not exceed once per day since it has been shown that more frequent administration may decrease IOP-lowering effect. Reduction of IOP starts approximately 3–4 h after administration and the maximum effect is reached after 8–12 h.
Latanoprost eye drops contraindications:
Patients with known hypersensitivity to the product or any of its components or to benzalkonium chloride.
Latanoprost eye drops Adverse Reactions:
Eyelash changes (increased length, thickness, pigmentation, and number of lashes); eyelid skin darkening; intraocular inflammation (iritis/uveitis); iris pigmentation changes; and macular edema, including cystoid macular edema, which have mainly occurred in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
Should be used with caution in patients who do not have an intact posterior capsule or who have known risk factors for macular edema and in patients with a history of intraocular inflammation (iritis/uveitis); should generally not be used in patients with active intraocular inflammation.
There is limited experience in the treatment of angle closure, inflammatory, or neovascularglaucoma.
Latanoprost eye drops ontrolled clinical trials:
Symptoms reported in 5–15% of patients— blurred vision, burning and stinging, conjunctival hyperemia, foreign-body sensation, itching, increased pigmentation of the iris, and punctate epithelial keratopathy.
Local conjunctival hyperemia was observed; however, less than 1% of the patients required discontinuation of therapy because of intolerance to conjunctival hyperemia.
Symptoms reported in 1–4% of patients—dry eye, excessive tearing, eye pain, lid crusting, lid discomfort/pain, lid edema, lid erythema, photophobia.
Symptoms reported in less than 1% of patients— conjunctivitis, diplopia, and discharge.
Extremely rare reports—retinal artery embolus, retinal detachment, vitreous hemorrhage from diabetic retinopathy.
Most common systemic adverse events—URTI/cold/flu, which occurred at a rate of approximately 4%.
Chest pain/angina pectoris, muscle/ joint/back pain, and rash/allergic skin reaction each occurred at a rate of 1–2%.
Postmarketing use in clinical practice: asthma and exacerbation of asthma; corneal edema and erosions; dyspnea; eyelash and vellus hair changes (increased length, thickness, pigmentation, and number); eyelid skin darkening; herpes keratitis; intraocular inflammation (iritis/uveitis); keratitis; macular edema, including cystoid macular edema;
misdirected eyelashes, sometimes resulting in eye irritation; toxic epidermal necrolysis.